Blackstone Inc’s Apogee Therapeutics APGE Stock Holding History

Blackstone Inc’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Buy	+12,090	New	+$1.09M	﹤0.01%	200
2026 Q1	–	Sell	-51,827	Closed	-$3.91M	–	419
2025 Q4	$3.91M	Sell	51,827 -138,525	-73%	-$8.73M	0.02%	138
2025 Q3	$7.56M	Buy	190,352 +11,806	+7%	+$451K	0.03%	105
2025 Q2	$7.75M	Sell	178,546 -5,201	-3%	-$198K	0.03%	92
2025 Q1	$6.86M	Buy	183,747 +103,747	+130%	+$4.01M	0.03%	91
2024 Q4	$3.62M	Hold	80,000	–	–	0.02%	102
2024 Q3	$4.7M	Hold	80,000	–	–	0.02%	97
2024 Q2	$3.15M	Sell	80,000 -150,000	-65%	-$7.28M	0.01%	108
2024 Q1	$15.3M	Sell	230,000 -121,810	-35%	-$5.32M	0.06%	76
2023 Q4	$9.83M	Buy	351,810 +52,688	+18%	+$1.06M	0.04%	69
2023 Q3	$6.37M	Buy	+299,122	New	+$6.59M	0.03%	91

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Blackstone Inc's APGE Position: Q2 2026 in Review

Blackstone Inc opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 12,090 shares worth $1.6M. The stake represents ﹤0.01% of the portfolio and ranks #200 among its holdings. This is a return to the name: Blackstone Inc previously reported a position in APGE as recently as Q4 2025.

Blackstone Inc first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. The position peaked at $15.3M in Q1 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Blackstone Inc held 12,090 shares of Apogee Therapeutics worth $1.6M as of Q2 2026.
Apogee Therapeutics was a new Blackstone Inc position in Q2 2026.
Apogee Therapeutics made up ﹤0.01% of Blackstone Inc's portfolio in Q2 2026, its #200 holding.
Blackstone Inc first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
Blackstone Inc's Apogee Therapeutics position peaked at $15.3M in Q1 2024.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.